As filed · Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Financial results for the period ended September 30, 2026. considered and approved the Unaudited limited reviewed Standalone & Consolidated Financial Results. review reports on standalone and consolidated quarterly financial results, issued by Mjs.
Reported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
Prior statements by this company that CapitSignal has recorded changing.
We'll probably have the exact number, say, after a few months' time.
as our cefiderocol project will get started, say, in the next year, then we will take validation batches and hopefully, after two years, we would be able to -- once we are able to register the product from our side, we would be able to supply some percentage from our side.
as our cefiderocol project will get started, say, in the next year, then we will take validation batches and hopefully, after two years, we would be able to -- once we are able to register the product from our side, we would be able to supply some percentage from our side.
So, as such -- we have not considered very significant capex in the next financial year.
So we hope we can continue between 10% to 15% again this year.
we hope to have better sales on Q-o-Q basis.
